论文部分内容阅读
分子靶向药物在分子水平干预肿瘤细胞的生长发育过程,不良反应相对较小,作用于细胞表面的分子靶向药物可与传统化疗药物联用,少有毒性叠加作用,特异性高。西妥昔单抗(cetuximab)是第一个在全球多个国家获准上市的靶向作用于表皮生长因子受体(EGFR)的IgG1单克隆抗体,为癌症患者的
Molecular targeted drugs intervene in the growth and development of tumor cells at the molecular level with relatively small adverse reactions. The molecularly targeted drugs acting on the cell surface can be combined with traditional chemotherapy drugs with little toxic superposition and high specificity. Cetuximab is the first IgG1 monoclonal antibody targeted to the epidermal growth factor receptor (EGFR) to be marketed in several countries around the world,